319 related articles for article (PubMed ID: 32375257)
1. Kaempferol and Its Glycoside, Kaempferol 7-O-Rhamnoside, Inhibit PD-1/PD-L1 Interaction In Vitro.
Kim JH; Kim YS; Choi JG; Li W; Lee EJ; Park JW; Song J; Chung HS
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32375257
[TBL] [Abstract][Full Text] [Related]
2. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
Front Immunol; 2021; 12():654463. PubMed ID: 34054817
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, evaluation, and SAR of 4-phenylindoline derivatives, a novel class of small-molecule inhibitors of the programmed cell death-1/ programmed cell death-ligand 1 (PD-1/PD-L1) interaction.
Yang Y; Wang K; Chen H; Feng Z
Eur J Med Chem; 2021 Feb; 211():113001. PubMed ID: 33272783
[TBL] [Abstract][Full Text] [Related]
4. Preparation of Biphenyl-Conjugated Bromotyrosine for Inhibition of PD-1/PD-L1 Immune Checkpoint Interactions.
Kim EH; Kawamoto M; Dharmatti R; Kobatake E; Ito Y; Miyatake H
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32455628
[TBL] [Abstract][Full Text] [Related]
5. Sanguisorbae Radix Suppresses Colorectal Tumor Growth Through PD-1/PD-L1 Blockade and Synergistic Effect With Pembrolizumab in a Humanized PD-L1-Expressing Colorectal Cancer Mouse Model.
Lee EJ; Kim JH; Kim TI; Kim YJ; Pak ME; Jeon CH; Park YJ; Li W; Kim YS; Choi JG; Chung HS
Front Immunol; 2021; 12():737076. PubMed ID: 34659228
[TBL] [Abstract][Full Text] [Related]
6. Rational design and development of a peptide inhibitor for the PD-1/PD-L1 interaction.
Boohaker RJ; Sambandam V; Segura I; Miller J; Suto M; Xu B
Cancer Lett; 2018 Oct; 434():11-21. PubMed ID: 29920293
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Programmed Death Receptor-1/Programmed Death Ligand-1 Interactions by Ginsenoside Metabolites.
Yim NH; Kim YS; Chung HS
Molecules; 2020 Apr; 25(9):. PubMed ID: 32365500
[TBL] [Abstract][Full Text] [Related]
8. Molecular Modeling Studies on the Binding Mode of the PD-1/PD-L1 Complex Inhibitors.
Almahmoud S; Zhong HA
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31546905
[TBL] [Abstract][Full Text] [Related]
9. Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2.
Zak KM; Grudnik P; Magiera K; Dömling A; Dubin G; Holak TA
Structure; 2017 Aug; 25(8):1163-1174. PubMed ID: 28768162
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 Inhibitors: Different Classes, Activities, and Mechanisms of Action.
Surmiak E; Magiera-Mularz K; Musielak B; Muszak D; Kocik-Krol J; Kitel R; Plewka J; Holak TA; Skalniak L
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769226
[TBL] [Abstract][Full Text] [Related]
11. Discovery of Novel Small-Molecule Inhibitors of PD-1/PD-L1 Interaction via Structural Simplification Strategy.
Zhang H; Xia Y; Yu C; Du H; Liu J; Li H; Huang S; Zhu Q; Xu Y; Zou Y
Molecules; 2021 Jun; 26(11):. PubMed ID: 34199417
[TBL] [Abstract][Full Text] [Related]
12. In vitro characterization of a small molecule PD-1 inhibitor that targets the PD-l/PD-L1 interaction.
Lu CH; Chung WM; Tsai CH; Cheng JC; Hsu KC; Tzeng HE
Sci Rep; 2022 Jan; 12(1):303. PubMed ID: 34996924
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and structure-activity relationship of programmed cell death-1/programmed cell death-ligand 1 interaction inhibitors bearing a benzo[d]isothiazole scaffold.
Chen H; Wang K; Yang Y; Huang X; Dai X; Feng Z
Eur J Med Chem; 2021 May; 217():113377. PubMed ID: 33770574
[TBL] [Abstract][Full Text] [Related]
14. Investigation of protein-protein interactions and hot spot region between PD-1 and PD-L1 by fragment molecular orbital method.
Lim H; Chun J; Jin X; Kim J; Yoon J; No KT
Sci Rep; 2019 Nov; 9(1):16727. PubMed ID: 31723178
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and biological evaluation of 1-methyl-1H-pyrazolo[4,3-b]pyridine derivatives as novel small-molecule inhibitors targeting the PD-1/PD-L1 interaction.
Dai X; Wang K; Chen H; Huang X; Feng Z
Bioorg Chem; 2021 Sep; 114():105034. PubMed ID: 34116264
[TBL] [Abstract][Full Text] [Related]
16. Insights into non-peptide small-molecule inhibitors of the PD-1/PD-L1 interaction: Development and perspective.
Wu X; Meng Y; Liu L; Gong G; Zhang H; Hou Y; Liu C; Wu D; Qin M
Bioorg Med Chem; 2021 Mar; 33():116038. PubMed ID: 33517226
[TBL] [Abstract][Full Text] [Related]
17. Conjugation of biphenyl groups with poly(ethylene glycol) to enhance inhibitory effects on the PD-1/PD-L1 immune checkpoint interaction.
Kim EH; Ning B; Kawamoto M; Miyatake H; Kobatake E; Ito Y; Akimoto J
J Mater Chem B; 2020 Nov; 8(44):10162-10171. PubMed ID: 33095222
[TBL] [Abstract][Full Text] [Related]
18. Development of a Non-IgG PD-1/PD-L1 Inhibitor by
Ning B; Ren X; Hagiwara K; Takeoka S; Ito Y; Miyatake H
ACS Chem Biol; 2021 Feb; 16(2):316-323. PubMed ID: 33448787
[TBL] [Abstract][Full Text] [Related]
19. Discovery of [1,2,4]Triazolo[4,3- a]pyridines as Potent Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction.
Qin M; Cao Q; Zheng S; Tian Y; Zhang H; Xie J; Xie H; Liu Y; Zhao Y; Gong P
J Med Chem; 2019 May; 62(9):4703-4715. PubMed ID: 30964291
[TBL] [Abstract][Full Text] [Related]
20. Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1).
Zak KM; Grudnik P; Guzik K; Zieba BJ; Musielak B; Dömling A; Dubin G; Holak TA
Oncotarget; 2016 May; 7(21):30323-35. PubMed ID: 27083005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
